Understanding heart problems caused by cancer treatment in patients with chronic lymphocytic leukemia.
Early Detection and Mechanisms of Cancer Immunotherapy Associated Cardiotoxicity
This study is looking at how the cancer drug ibrutinib might affect heart health in people with chronic lymphocytic leukemia (CLL), especially focusing on heart rhythm problems, and it aims to find ways to keep your heart safe while you’re being treated.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10897227 on NIH RePORTER |
What this research studies
This research investigates how the cancer treatment ibrutinib affects heart health, specifically looking at the development of atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). The study will involve monitoring patients' heart structure and function using advanced imaging techniques before and after starting treatment. Researchers aim to identify the mechanisms behind heart issues related to ibrutinib, including changes in heart size and tissue composition, as well as the impact of blood pressure changes. By understanding these factors, the research seeks to develop strategies to prevent heart complications in patients undergoing this treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with chronic lymphocytic leukemia who are starting treatment with ibrutinib.
Not a fit: Patients not receiving ibrutinib or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart health management for patients undergoing treatment for chronic lymphocytic leukemia.
How similar studies have performed: Previous research has shown that understanding treatment-related complications can lead to better management strategies, indicating potential success for this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Addison, Daniel — Ohio State University
- Study coordinator: Addison, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.